ClinicalTrials.gg
RecruitingNCT07553728Updated Oct 28, 2026

Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART)

An observational study in Infertility, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 36 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
36 Years to 39 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Infertility with a site in China — 38 open to participants now, 41 under way, 5 of them phase 3. Infertility · China.

Planned enrollment
25th of 32
200 · median 550
Started
2026
with 7 others
Observational
32 of 139
7 open now
Primary completion
2029-08
later than 37 of 40 live
Registered
134th of 139
by date
Lead sponsor
4 of 139
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 139 studies in Infertility with a site in China, this one is the 25th largest by planned enrollment of the 32 observational ones that give a count, is one of 8 that started in 2026, is one of 32 observational ones, reaches primary completion later than 37 of the 40 other live ones, and was the 134th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

38 of the 139 studies in Infertility with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 36 Years to 39 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Infertility with a site in China, or all of them as a file.
02

Study summary

This is a multi-centre, single-arm, observational trial to assess the safety and efficacy of corifollitropin alfa N02 Injection in elderly Chinese women undergoing ART, and then to explore the compliance and satisfaction during COS treatment.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • assisted reproductive technology (ART)
  • controlled ovarian stimulation (COS)
04

Who can participate

Ages eligible
36 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Married women aged 36-39 years scheduled for controlled ovarian stimulation (COS) and IVF/ICSI assisted reproduction using a fixed antagonist protocol with Corifollitropin alfa N02 Injection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to communicate well with investigators, understand and comply with trial requirements, participate voluntarily, and provide signed after full understanding.
  2. Married women aged 36 to 40 years (exclusive of boundary values).
  3. Normal ovarian function: AMH ≥ 1.1 μg/L and basal FSH \< 10 IU/L.
  4. Scheduled to undergo controlled ovarian stimulation (COS) and IVF/ICSI using a fixed antagonist protocol combined with Corifollitropin alpha N02 injection.

Exclusion criteria

Exclusion Criteria:

  1. ≥3 previous cycles of controlled ovarian stimulation (COS)
  2. Recurrent pregnancy loss: ≥3 previous pregnancy losses (including spontaneous abortion, biochemical pregnancy, and missed abortion).
  3. Repeated implantation failure: ≥3 embryo transfer cycles (fresh or frozen) or failure to achieve clinical pregnancy after transfer of ≥4 high-quality embryos in total.
  4. High risk of ovarian hyperstimulation syndrome (OHSS), defined by any of the following:

    • Diagnosed with polycystic ovary syndrome (PCOS);

      • Total number of AFC in both ovaries >20 on Day 2-3 of menstruation; ③ Previous cycle cancellation (including canceled embryo transfer) due to high ovarian response or high OHSS risk; ④ History of OHSS; ⑤ Other conditions judged by the investigator to confer high OHSS risk after comprehensive evaluation.
  5. Poor ovarian function, defined by any of the following:

    ① Previous poor ovarian response (≤3 oocytes retrieved following conventional full-dose gonadotropin stimulation);

    ② Total AFC in both ovaries \<5.

  6. Presence of any reproductive, endocrine, or immune disorders that may affect pregnancy, as assessed by the investigator.
  7. Abnormal uterine bleeding.
  8. Presence of systemic diseases (e.g., cardiovascular, digestive, neurological, hematological disorders) deemed unsuitable for study participation by the investigator, or severe diseases incompatible with pregnancy.
  9. or history of allergy to active ingredients or of gonadotropins (Gn), GnRH antagonists, or progesterone preparations, or with documented to these medications.
  10. History of alcoholism, heavy smoking, drug addiction, or substance abuse.
  11. Scheduled to undergo preimplantation genetic testing (PGT).
  12. Currently participating in another clinical trials and receiving products.
  13. Any other conditions deemed by the investigator to render the subject unsuitable for trial participation based on safety considerations.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Corifollitropin alfa N02 Injection

    Observe and record the safety and efficacy data of women receiving controlled ovarian stimulation therapy using Corifollitropin alfa N02 Injection

    Other: NA,Observational study

Interventions

  • OtherNA,Observational study

    Data will be collected without interfering with routine clinical care.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: From signing the ICF to the birth of the newborn

Secondary outcomes

  1. Incidence of early-onset ovarian hyperstimulation syndrome (OHSS)

    Time frame: Up to 9 days after triggering of final follicular maturation

  2. Incidence of moderate to severe OHSS

    Time frame: Up to 10-11 weeks after transfer

  3. fetal/newborn birth defects

    Time frame: Up to 15 months

  4. 1-year cumulative clinical pregnancy rate per initiated stimulation cycles

    Time frame: 4 to 6 weeks after last frozen embryo transfer

  5. 1-year cumulative ongoing pregnancy rate per initiated stimulation cycles

    Time frame: 9 to 11 weeks after last frozen embryo transfer

  6. 1-year cumulative live birth rate per initiated stimulation cycles

    Time frame: more than 40 weeks after last frozen embryo transfer

  7. β-hCG/hCG positive rate per initiated stimulation cycles with fresh embryo transfer

    Time frame: 4 weeks after fresh embryo transfer

  8. Clinical pregnancy rate per initiated stimulation cycles with fresh embryo transfer

    Time frame: 4 to 6 weeks after fresh embryo transfer

  9. Ongoing pregnancy rate per initiated stimulation cycles with fresh embryo transfer

    Time frame: 9 to 11 weeks after fresh embryo transfer

  10. Live birth rate per initiated stimulation cycles with fresh embryo transfer

    Time frame: more than 40 weeks after fresh embryo transfer

  11. β-hCG/hCG positive rate per initiated stimulation cycles with first embryo transfer cycle

    Time frame: 4 weeks after first embryo transfer

  12. Clinical pregnancy rate per initiated stimulation cycles with first embryo transfer cycle

    Time frame: 4 to 6 weeks after first embryo transfer

  13. Ongoing pregnancy rate per initiated stimulation cycles with first embryo transfer cycle

    Time frame: 9 to 11 weeks after first embryo transfer

  14. Live birth rate per initiated stimulation cycles with first embryo transfer cycle

    Time frame: more than 40 weeks after first embryo transfer

  15. Pregnancy loss rate

    Time frame: Up to 38 weeks after transfer

  16. Number of oocytes retrieved

    Time frame: Up to 22 days

  17. Estrogen (E₂) and progesterone (P) levels during controlled ovarian stimulation (COS)

    Time frame: Up to 22 days

  18. Follicular development status

    Time frame: Up to 22 days

  19. Metaphase II (MII) oocyte rate [evaluated only in intracytoplasmic sperm injection (ICSI) cycles]

    Time frame: Up to 22 days

  20. Fertilization rate Implantation rate

    Time frame: Day 3 after oocyte retrieval

  21. Implantation rate

    Time frame: Up to 28 days

  22. High-quality embryo rate

    Time frame: Day 3 after oocyte retrieval

  23. Usable blastocyst formation rate

    Time frame: Day 5 after oocyte retrieval

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Aug 2029, 39 months after the start.

Of 240 observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 99. This study's planned 39 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Apr 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 28, 2026
StartActual
Apr 30, 2026was May 2026
Primary completionEst.
Aug 4, 2029
CompletionEst.
Dec 16, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
Peking University Third Hospital is now Recruiting
Oct 28, 2026
Start date
May 1, 2026→Apr 30, 2026 (actual)
Oct 28, 2026
Eligibility
Maximum age 40 Years→39 Years
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    Peking University Third Hospital is now Recruiting
    Start date May 1, 2026→Apr 30, 2026 (now actual)
    Eligibility Maximum age 40 Years→39 Years

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07553728
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
Apr 30, 2026
Primary completion
Aug 4, 2029 (estimated)
Completion
Dec 16, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Mengsheng Zhang
Contact
zhangmengsheng@genscigroup.com
+86 18190952182

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion